ELEKTA'S WARRANTS PROGRAM

ELEKTA'S WARRANTS PROGRAM Elekta's Board of Directors has decided not to put forward a suggestion on a new warrants program at the Annual General Meeting on 30 September 2002. The reorganization of Elekta, announced on 18 June 2002 must first be fully implemented. The subscription period for the first issue of the warrants program for managers and key persons within the company, approved by the shareholders at an Extraordinary General Meeting on 17 November 1999, will expire on 1 December 2002. The program consists of a total of 500,000 warrants. Approximately 100,000 of those have so far been exercised for subscription of new Series B shares. The subscription price is SEK 50 since 1 December 2001. Before the expiration of the subscription period on 1 December 2002, participants in this warrants program, including managers, may exercise their warrants and subscribe for new Series B shares and thereafter possibly sell their shares. During 2000-2001 another two warrants programs have been approved by the shareholders at Shareholders' Meetings. The subscription period for those programs is 1 January 2001 - 30 September 2004. In total Elekta's three warrants programs include 2,500,000 warrants. Warrant holders have the right to subscribe for one new Series B share for one warrant. ***** Elekta is a world-leading supplier of advanced and innovative radiation oncology and neurosurgery solutions and services for precise treatment of cancer and brain disorders. Elekta's solutions are clinically effective, cost efficient and gentle to the patient. For further information, please contact: Lars Jonsteg, VP Communications, Elekta AB (publ), tel. +46 8 587 254 82 More information about Elekta can be found at: www.elekta.com ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2002/06/28/20040826BIT21480/wkr0001.pdf

About Us

For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.

Subscribe

Documents & Links